Integrating upstream host cell line selection and development with improved downstream bioprocessing
将上游宿主细胞系选择和开发与改进的下游生物加工相结合
基本信息
- 批准号:BB/G010358/1
- 负责人:
- 金额:$ 46.1万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2009
- 资助国家:英国
- 起止时间:2009 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Many of the new drugs currently under development are based upon proteins rather than traditional small molecules (e.g. antibiotics). One of the type of protein molecules that is particularly challenging to make are antibodies e.g. herceptin. These protein drugs are produced for the treatment of diseases such as cancer by mammalian cells kept in culture under defined conditions. One problem with this is that the cells we use to make such proteins secrete not only the target protein into the medium in which the cells grow, but other proteins from the cell as well, called host cell proteins (HCPs). Further, cell breakage during fermentation or downstream handling (e.g. centrifugation) can result in the release of intracellular protein material. To complicate things further, what these HCPs are (the contaminants) and how they change throughout cell fermentation and with target products is not known. What this means is that the target drug must be purified from the rest of the material in the medium before it is deemed safe for use and this is referred to as downstream bioprocessing. Downstream bioprocessing is now a major part (>40%) of the total cost of manufacturing such drugs and as such improvements in this area would be of major benefit to both manufacturers and the end patient. We aim to begin addressing this lack of knowledge with respect to the HCPs in the medium during the culturing of Chinese hamster ovary cells engineered to express a recombinant monoclonal antibody. Specifically, we will determine the HCP profile throughout culture and throughout a standard template purification procedure for a monoclonal antibody. We intend to use this information to then remove the most troublesome HCPs by cell engineering approaches and determine what effect this has on product yield, cell growth and subsequent purification procedures. Ultimately we envisage that this information will allow us to redesign downstream purification procedures either to remove or to integrate better current chromatographic steps which are expensive and time consuming. This information is of high industrial relevance since the production of commercially valuable proteins (e.g. antibodies) can be hindered, and the cost dramatically escalated, as a result of the multiple chromatographic steps currently required to purify the target protein to acceptable levels. A better understanding of the HCP profile and how this influences downstream processing is very important as it is expected that with an increasing number of protein 'drugs' being developed we will lack the capability of producing large enough amounts to meet the required demand at a cost which can be affordable for the majority. Hence these products remain prohibitively expensive to many, but very effective, medicines.
目前正在开发的许多新药都是基于蛋白质而不是传统的小分子(例如抗生素)。其中一种特别具有挑战性的蛋白质分子是抗体,例如赫赛汀。这些蛋白质药物是通过在特定条件下培养的哺乳动物细胞生产出来的,用于治疗癌症等疾病。这样做的一个问题是,我们用来制造这种蛋白质的细胞不仅将目标蛋白质分泌到细胞生长的介质中,还会分泌来自细胞的其他蛋白质,称为宿主细胞蛋白(Hcps)。此外,发酵或下游处理(如离心法)过程中的细胞破碎会导致细胞内蛋白质物质的释放。让事情更复杂的是,这些HCP是什么(污染物),以及它们在整个细胞发酵过程中如何变化以及与目标产品的关系尚不清楚。这意味着目标药物必须从介质中的其余材料中提纯,然后才被认为是安全使用的,这被称为下游生物加工。下游生物加工现在是制造这类药物的总成本的主要部分(40%),因此这一领域的改进将对制造商和最终患者都有重大好处。我们的目标是开始解决在培养中国仓鼠卵巢细胞的过程中对培养液中HCP缺乏了解的问题,这些细胞被设计成表达重组单抗。具体地说,我们将在整个培养过程和标准的单抗模板纯化过程中确定hCP的分布。我们打算利用这些信息通过细胞工程方法去除最麻烦的HCP,并确定这对产品产量、细胞生长和后续纯化过程有什么影响。最终,我们预计这些信息将使我们能够重新设计下游纯化程序,以删除或整合更好的当前色谱分析步骤,这些步骤既昂贵又耗时。这一信息具有很高的工业相关性,因为由于目前需要进行多个层析步骤来将目标蛋白纯化到可接受的水平,因此可能会阻碍具有商业价值的蛋白质(例如抗体)的生产,并且成本会急剧上升。更好地了解HCP的概况以及这如何影响下游加工是非常重要的,因为预计随着越来越多的蛋白质“药物”的开发,我们将无法以大多数人能够负担得起的成本生产足够大的数量来满足所需的需求。因此,这些产品对许多但非常有效的药物来说仍然昂贵得令人望而却步。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Host cell protein dynamics in recombinant CHO cells Impacts from harvest to purification and beyond
- DOI:10.4161/bioe.23382
- 发表时间:2013-09-01
- 期刊:
- 影响因子:4.9
- 作者:Hogwood, Catherine E. M.;Bracewell, Daniel G.;Smales, C. Mark
- 通讯作者:Smales, C. Mark
The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control.
- DOI:10.1002/bit.25628
- 发表时间:2015-09
- 期刊:
- 影响因子:3.8
- 作者:Bracewell DG;Francis R;Smales CM
- 通讯作者:Smales CM
UV resonance Raman spectroscopy: a process analytical tool for host cell DNA and RNA dynamics in mammalian cell lines
紫外共振拉曼光谱:哺乳动物细胞系宿主细胞 DNA 和 RNA 动力学的过程分析工具
- DOI:10.1002/jctb.4420
- 发表时间:2014
- 期刊:
- 影响因子:3.4
- 作者:Ashton L
- 通讯作者:Ashton L
The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process
- DOI:10.1002/bit.24607
- 发表时间:2013-01-01
- 期刊:
- 影响因子:3.8
- 作者:Hogwood, Catherine E. M.;Tait, Andrew S.;Smales, C. Mark
- 通讯作者:Smales, C. Mark
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Bracewell其他文献
Characterisation of the bioreactor environment and its effect on mammalian cell performance in suspension culture during antibody production
抗体生产期间悬浮培养中生物反应器环境的表征及其对哺乳动物细胞性能的影响
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:0
- 作者:
María de Lourdes Vélez Suberbie;Felipe Suberbie Mendiola;Lourdes Vélez Suberbie;Daniel Bracewell - 通讯作者:
Daniel Bracewell
Daniel Bracewell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Bracewell', 18)}}的其他基金
Smart biomanufacturing for genomic medicines
基因组药物的智能生物制造
- 批准号:
EP/X025446/1 - 财政年份:2024
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
Digital design and fabrication of advanced biopurification materials
先进生物净化材料的数字化设计和制造
- 批准号:
MR/W004399/1 - 财政年份:2021
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
Development and optimisation of downstream processing for next generation biotherapeutics
下一代生物治疗药物下游加工的开发和优化
- 批准号:
EP/N013395/1 - 财政年份:2016
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
Nanofibre scale-up and industrial validation - Industrial Biotechnology Catalyst Translation and Industrial Research Awards
纳米纤维放大和工业验证 - 工业生物技术催化剂转化和工业研究奖
- 批准号:
EP/M017222/1 - 财政年份:2015
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
13TSB_TIBio: Technology Inspired Innovation Bioscience - Puridify
13TSB_TIBio:技术启发创新生物科学 - Puridify
- 批准号:
BB/M004848/1 - 财政年份:2014
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
Creation of a process understanding of chromatographic performance loss during biotherapeutic manufacture: A UK-India partnership
创建生物治疗药物生产过程中色谱性能损失的流程理解:英国-印度合作伙伴关系
- 批准号:
EP/K029053/1 - 财政年份:2014
- 资助金额:
$ 46.1万 - 项目类别:
Research Grant
BRIC DOCTORATE PROGRAMME - Understanding on-column protein aggregation and its impact on bioprocessing
金砖四国博士项目 - 了解柱上蛋白质聚集及其对生物加工的影响
- 批准号:
BB/J003832/1 - 财政年份:2011
- 资助金额:
$ 46.1万 - 项目类别:
Training Grant
相似海外基金
Translational Regulation of SARS-CoV-2 in response to viral S protein-induced signaling
SARS-CoV-2 响应病毒 S 蛋白诱导信号传导的翻译调控
- 批准号:
10721101 - 财政年份:2023
- 资助金额:
$ 46.1万 - 项目类别:
Productive and latent HIV infection of microglia: virus and host wrestle for SUMOylation system control
小胶质细胞的生产性和潜伏性 HIV 感染:病毒和宿主为控制 SUMO 化系统而斗争
- 批准号:
10748561 - 财政年份:2023
- 资助金额:
$ 46.1万 - 项目类别:
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10373575 - 财政年份:2021
- 资助金额:
$ 46.1万 - 项目类别:
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10495267 - 财政年份:2021
- 资助金额:
$ 46.1万 - 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
- 批准号:
10394983 - 财政年份:2020
- 资助金额:
$ 46.1万 - 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
- 批准号:
10623146 - 财政年份:2020
- 资助金额:
$ 46.1万 - 项目类别:
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
TRIM23 在自噬介导的抗病毒防御中的作用
- 批准号:
10353335 - 财政年份:2020
- 资助金额:
$ 46.1万 - 项目类别:
Persistence of HCV-Induced Perturbations of Cellular Pathways Post DAA Cure in Advanced Liver Disease
DAA 治愈晚期肝病后 HCV 诱导的细胞通路扰动的持续存在
- 批准号:
10118278 - 财政年份:2020
- 资助金额:
$ 46.1万 - 项目类别:
Role of AMP-activated protein kinase in bacterial endophthalmitis
AMP 激活蛋白激酶在细菌性眼内炎中的作用
- 批准号:
9899998 - 财政年份:2017
- 资助金额:
$ 46.1万 - 项目类别: